immunocore-logo-2018
Immunocore to present at the 2024 Cantor Global Healthcare Conference
September 12, 2024 16:05 ET | Immunocore Holdings plc
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq:...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Reports Results of Annual General Meeting
June 24, 2024 11:05 ET | Medigene AG
Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new...
immunocore-logo-2018
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
June 18, 2024 07:00 ET | Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
immunocore-logo-2018
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024 08:00 ET | Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
immunocore-logo-2018
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
May 31, 2024 16:05 ET | Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
immunocore-logo-2018
Immunocore to present at the Jefferies Global Healthcare Conference
May 30, 2024 16:00 ET | Immunocore Holdings plc
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
TCR UK
TCR UK and Woya Digital Renew Marketing Partnership for 2024
May 10, 2024 12:32 ET | TCR UK
Birmingham, UK, May 10, 2024 (GLOBE NEWSWIRE) -- TCR UK and Woya Digital Renew Marketing Partnership for 2024 TCR UK is thrilled to announce the renewal of its marketing partnership with Woya...
immunocore-logo-2018
Immunocore reports first quarter financial results and provides a business update
May 08, 2024 07:00 ET | Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
Sport77 and J.A.S Mo
Sport77 and J.A.S Motorsport Announces New UK Motorsport Partnership
March 08, 2024 10:02 ET | Sport77 Ltd
London, UK, March 08, 2024 (GLOBE NEWSWIRE) -- Sport77 and J.A.S Motorsport are pleased to announce a new association that will increase support and access to Honda racing products in the United...
immunocore-logo-2018
Immunocore presented two posters at CROI 2024
March 05, 2024 16:30 ET | Immunocore Holdings Limited
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...